Skip to content

The effect of clove in depression

Phytochemical evaluation and clinical effect of Syzygium aromaticum in comparison with the control group on reducing depression in depressive patients: a triple-blind randomized clinical trial

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20211223053499N1
Enrollment
70
Registered
2022-01-21
Start date
2022-01-24
Completion date
Unknown
Last updated
2023-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Major depressive disorder, single episode, moderate. Condition 2: Major depressive disorder, single episode, mild. Condition 3: Major depressive disorder, recurrent, mild. Condition 4: Major depressive disorder, recurrent, moderate. Condition 5: Major depressive disorder, single episode, severe without psychotic features. Condition 6: Major depressive disorder, recurrent severe without psychotic features. Condition 7: Bipolar disorder, current episode depressed, mild or moderate sev

Interventions

Intervention 1: Intervention group: 2 months of standard treatment (sertraline) + inhalation of one puff per day of 5% clove essential oil (diluted in ethanol) applied to the collar of the shirt + pla

Sponsors

Hamedan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Aged 18 to 65 years A patient with major depressive disorder or bipolar disorder in the depressive episode

Exclusion criteria

Exclusion criteria: Existence of psychotic symptoms Cognition disorders Anxiety disorders Schizophrenia Antisocial personality disorder Mental retardation Dementia Pregnancy Lactation Explicit suicidal ideation History of allergy to herbal drugs Having a proven problem with the sense of smell

Design outcomes

Primary

MeasureTime frame
Depression rate. Timepoint: Weeks 0, 4 and 8 after the start of the intervention. Method of measurement: Hamilton Depression Inventory 17 items and Clinical Global Impression Questionnaire.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSara Javan

Hamedan University of Medical Sciences

sarajavan2014@gmail.com+98 81 3838 0548

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026